Back to Search
Start Over
Disease Burden and Patient-Reported Outcomes Among Ulcerative Colitis Patients According to Therapy at Enrollment Into CorEvitas' Inflammatory Bowel Disease Registry.
- Source :
-
Crohn's & colitis 360 [Crohns Colitis 360] 2022 Mar 08; Vol. 4 (3), pp. otac007. Date of Electronic Publication: 2022 Mar 08 (Print Publication: 2022). - Publication Year :
- 2022
-
Abstract
- Background: To evaluate disease burden and patient-reported outcomes (PROs) of ulcerative colitis (UC) patients at enrollment into CorEvitas' Inflammatory Bowel Disease Registry by therapy class.<br />Methods: Between May 3, 2017 and September 3, 2019, 773 UC registry patients were categorized by therapy class at enrollment: patients on 5-aminosalicylic acids (5-ASAs) only ( n = 290), and patients on biologics/Janus kinase inhibitors (JAKi) alone or in combination with 5-ASAs or immunosuppressant therapies (BIO/JAKi) ( n = 315). To quantify between group differences, the mean/proportional differences and corresponding 95% CIs were calculated.<br />Results: Among 605 UC patients at enrollment, BIO/JAKi patients were younger (44.1 vs. 50.9 years) more were female (58.0% vs. 49.7%), had lower remission (45.4% vs. 60.0%), had more moderate/severe disease (16.5% vs. 7.1%), experienced less proctitis (10.5% vs. 22.1%), but more pancolitis (54.6% vs. 34.1%), more corticosteroid experience (70.8% vs. 44.5%), previous biologic experience (1 prior: 21.6% vs. 2.4%; 2+ prior: 12.1% vs. 0.3%), and shorter duration of current UC therapy (1.6 vs. 3.5 years) than 5-ASAs patients. BIO/JAKi patients had higher current employment than 5-ASAs patients (70.7% vs. 62.4%) and higher mean Work Productivity and Activity Impairment (WPAI) domains for absenteeism (7.3 vs. 2.8) and activity impairment (22.0 vs. 17.5).<br />Conclusions: Among UC patients in a real-world setting, BIO/JAKi patients had less remission, more moderate-to-severe disease, and worse PROs than 5-ASAs patients. These results suggest that despite increased therapeutic options, patients with UC currently being treated with biologics or JAKi may still experience disease burden and continued unmet needs.<br /> (© The Author(s) 2022. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.)
Details
- Language :
- English
- ISSN :
- 2631-827X
- Volume :
- 4
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Crohn's & colitis 360
- Publication Type :
- Academic Journal
- Accession number :
- 36777423
- Full Text :
- https://doi.org/10.1093/crocol/otac007